EFFECT OF A SELECTIVE C5AR ANTAGONIST, AVACOPAN (CCX168), ON PLASMA COMPLEMENT LEVELS IN ANCA ASSOCIATED VASCULITIS (AAV)

被引：2
|
作者：
Bunch, D. O. [1 ]
Deng, J. [2 ]
McInnis, E. A. [1 ]
Bekker, P. [2 ]
Hillson, J. L. [2 ]
Schall, T. J. [2 ]
Jennette, C. J. [3 ]
Nachman, P. [1 ]
Deng, J. [2 ]
机构：
[1] Univ N Carolina, Kidney Ctr, Chapel Hill, NC 27515 USA
[2] Chemocentryx, 850 Maude Ave, Mountain View, CA USA
[3] Univ N Carolina, Dept Pathol, Chapel Hill, NC 27515 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.6032
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0046
引用
收藏
页码：74 / 75
页数：2
相关论文
共 21 条
  • [1] A Randomized Clinical Trial of CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with ANCA-Associated Vasculitis
    Merkel, Peter A.
    Niles, John
    Jimenez, Richard
    Spiera, Robert F.
    Rovin, Brad H.
    Bomback, Andrew
    Pagnoux, Christian
    Potarca, Antonia
    Schall, Thomas J.
    Bekker, Pirow
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [2] C5aR inhibitor on leukocytes exploratory ANCA associated renal vasculitis (CLEAR) clinical trial with orally administered CCX168
    Bruchfeld, A.
    Schaier, M.
    Jadoul, M.
    Selga, D.
    Szombati, I.
    Venning, M.
    Hamilton, P.
    Ciechanowski, K.
    Hugo, C.
    Segelmark, M.
    Viklicky, O.
    Jaen, J.
    Schall, T.
    Bekker, P.
    PRESSE MEDICALE, 2013, 42 (04): : 768 - 769
  • [3] CHARACTERIZATION OF THE NOVEL C5AR ANTAGONIST CCX168, A POTENTIAL THERAPEUTIC FOR ANCA-VASCULITIS, RHEUMATOID ARTHRITIS, AND OTHER AUTOIMMUNE DISORDERS
    Powers, J. P.
    Bekker, P. J.
    Dairaghi, D. J.
    Jennette, J. C.
    Johnson, D. A.
    Leleti, M.
    Miao, S.
    Seitz, L. C.
    Wang, Y.
    Xiao, H.
    Schall, T. J.
    Jaen, J. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 124 - 124
  • [4] CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Bekker, Pirow
    Jayne, David
    Bruchfeld, Annette
    Schaier, Matthias
    Ciechanowski, Kazimierz
    Harper, Lorraine
    Jadoul, Michel
    Segelmark, Marten
    Selga, Daina
    Szombati, Istvan
    Venning, Michael
    Hugo, Christian
    van Daele, Paul L.
    Viklicky, Ondrej
    Potarca, Antonia
    Schall, Thomas J.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S820 - S820
  • [5] ORAL C5A RECEPTOR ANTAGONIST CCX168 PHASE 2 CLINICAL TRIAL IN ANCA-ASSOCIATED RENAL VASCULITIS
    Jayne, D. R.
    Bruchfeld, A.
    Schaier, M.
    Ciechanowski, K.
    Harper, L.
    Jadoul, M.
    Segelmark, M.
    Selga, D.
    Szombati, I.
    Venning, M.
    Hugo, C.
    Van Daele, P. L.
    Viklicky, O.
    Potarca, A.
    Schall, T. J.
    Bekker, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 148 - 148
  • [6] ORAL C5A RECEPTOR ANTAGONIST CCX168 IN A PHASE 2 CLINICAL TRIAL IN ANCA-ASSOCIATED RENAL VASCULITIS
    Bekker, Pirow
    Potarca, Antonia
    Dairaghi, Daniel
    Miao, Shichang
    Powers, Jay P.
    Jaen, Juan C.
    Schall, Thomas J.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 419 - 420
  • [7] PHASE 2 RANDOMISED TRIAL OF ORAL C5A RECEPTOR ANTAGONIST CCX168 IN ANCA-ASSOCIATED RENAL VASCULITIS
    Jayne, David R. W.
    Bruchfeld, Annette
    Schaier, Matthias
    Ciechanowski, Kazimierz
    Harper, Lorraine
    Jadoul, Michel
    Segelmark, Marten
    Selga, Daina
    Szombati, Istvan
    Venning, Michael
    Hamilton, Patrick
    Hugo, Christian
    Van Daele, Paul L. A.
    Viklicky, Ondrej
    Potarca, Antonia
    Schall, Thomas J.
    Bekker, Pirow
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 27 - 27
  • [8] CLINICAL DOSE SELECTION OF THE C5A RECEPTOR ANTAGONIST CCX168 FOR THE PHASE 2 ANCA-ASSOCIATED RENAL VASCULITIS CLINICAL TRIAL (THE CLEAR TRIAL)
    Dairaghi, Daniel
    Johnson, Daniel
    Leleti, Manmohan
    Miao, Shichang
    Xiao, Hong
    Jennette, J. Charles
    Powers, Jay P.
    Seitz, Lisa
    Wang, Yu
    Jaen, Juan C.
    Schall, Thomas J.
    Bekker, Pirow
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 401 - 402
  • [9] Use of avacopan in severe forms of ANCA-associated vasculitis. Comment on ?Inhibiting C5a/C5aR to treat ANCA-associatedvasculitides
    Astouati, Quentin
    Provot, Francois
    Farhat, Meryem-Maud
    Launay, David
    Sanges, Sebastien
    JOINT BONE SPINE, 2023, 90 (02)
  • [10] SUCCESSFUL STEROID REPLACEMENT IN ANCA-ASSOCIATED VASCULITIS WITH C5A RECEPTOR INHIBITOR CCX168 IN PHASE 2 RANDOMISED TRIAL (CLEAR)
    Jayne, David
    Bruchfeld, Annette
    Harper, Lorraine
    Schaier, Matthias
    Venning, Michael
    Hamilton, Patrick
    Burst, Volker
    Grundman, Franziska
    Jadoul, Michel
    Szombati, Istvan
    Tesar, Vladimir
    Segelmark, Marten
    Potarca, Antonia
    Schall, Thomas J.
    Bekker, Pirow
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 45 - 45
123